



# Effective Medications in Vestibular Migraine

## A Case Report

Nallipogu Sai Tulasi<sup>1\*</sup>, P.Twila Pushpa<sup>1</sup>, Polamuri Havila<sup>2</sup>, Mekala Swathi Kiran<sup>3</sup>

<sup>1\*,2,3</sup>-Doctor of pharmacy practice, Bharat Institution of Technology, managalgally, Ibrahimpatam, Hyderabad, Ranga reddy dt, Telangana, INDIA 501510.

1-Assistant Professor, Bharat Institution of Technology, managalgally, Ibrahimpatam, Hyderabad, Ranga reddy dt, Telangana, INDIA 501510.

### **ABSTRACT:**

Vestibular Migraine is a type of migraine where people experience a combination of vertigo, dizziness or balance problems with other migraine symptoms. Vestibular Migraine is evaluated to be the 2<sup>nd</sup> most common cause of episodic vertigo. It is referred with other terms such as Migrainous vertigo, Migraine related dizziness or Migraine with prominent vertigo. About 40% of population experience various kinds of migraines associated with severe headaches, Nausea, vomiting, dizziness and others. Migraine can affect the vestibular system of the inner ear which shows impact on the control mechanisms of brain which give rise to vestibular migraine. A 55years old female patient was admitted in Internal Medicine department of KIMS-Rasoolpura (Krishna Institute of Medical Sciences) with chief complaints of giddiness, fever, headache and vomiting since 5days. Her personal history showed that her appetite, sleep, bowel and bladder habits were abnormal. She was treated with the prophylactic treatment such as cinnarizine and flunarizine and other supportive medication like betahistine and clorazepam etc which improved the patient condition within 7 days duration. Thus the hint of this written report is to say that, the management of the vestibular migraine with cinnarizine and flunarizine will show a better result in the patient.

### **INTRODUCTION:**

Vestibular Migraine is a nervous system problem that causes frequent episodes of vertigo(or dizziness) in people with history of migraine symptoms. Migraines are often accompanied with painful headaches but whereas in case of vestibular migraines, people usually doesn't experience any kind of headache. In addition to vertigo people may feel off-balance and light-headed. This Vestibular migraine may last long for few seconds or minutes, in some cases they persevere for days. Only about 1% of population are been shown to have vestibular migraine. Science isn't precise about the complex mechanisms of migraine, but few believe that the abnormal release of chemicals in brain may play a role. On the other hand, one theory suggests that migraine relates to an unusual electrical charge in the neurons that sets off the brain's pain receptors. Another theory suggests that migraine may be related to changes in serotonin in the brain.

Few known factors that trigger vestibular migraine includes-

- Stress and anxiety
- Poor sleep-both too little, and too much.
- Hunger and dehydration – missing meals and not taking enough water.
- Dietary triggers – caffeine, red wine, processed food, monosodium glutamate, aged cheeses.
- Hormonal changes – i.e. menstruation, menopause and in teenagers.

Other than vertigo, Vestibular migraine is entailed with symptoms like-

- Nausea and vomiting
- Sensitivity to motion, light, sound and smell
- Unsteadiness and loss of balance
- Tinnitus
- Problems with vision
- Feeling of pressure in the head or the ear
- A numb or tingling feeling

Children may also experience episodes similar to vestibular migraines. In children, it is known as “benign paroxysmal vertigo of childhood.” These children are more likely than others to experience migraines later in life. Women are more susceptible to vestibular migraine and may get severe around during their menstruation. According to few studies vestibular migraine is said to be hereditary but not yet well defined.

### **Case Report:**

A 55yrs old female patient was admitted in the Internal Medicine department of KIMS-Rasoolpura(Krishna Institute of Medical Sciences) with her chief complaints of giddiness,fever,headache and vomiting since 5days. Her past medical history says that she was taking laxative(duphalac oral solution,BD) for constipation and CNS depressants (Tab Chloradiazepoxide-5mg,OD) for insomnia. Her personal history and habits were- diet was mixed, appetite was abnormal, sleep was abnormal, bowel and bladder habits were abnormal and there is found to be no allergies to food, drugs and others. On general examination she was conscious. On physical examination her vitals found to be- BP was 160/90mmHg, pulse rate was 108 beats/min, respiratory rate was 24beats/min, oxygen saturation was 95% and she was suffering with fever of 101F. Systemic Examination reveals that her CVS was S1,S2+, RS was B/L AE, P/A was soft, CNS was NAD. For further confirmation she was subjected to laboratory investigations which are as follows- Potassium levels have been decreased to 3.0mEq/L. In Diffusion imaging, small vessel ischemic changes were observed which indicates decreased blood flow which is responsible for triggering migraine. Ultrasound and ECG were also suggested. And finally Vestibular Migraine/ Vertiginous Migraine was been the Conformatory Diagnosis. As she was been admitted in the hospital, on the 1<sup>st</sup> day there was complaints of vomiting, dizziness, insomnia and vitals were same as above mentioned. So she was been treated with medications like Inj. ZOFER-8mg-OD-iv; Dulcolax Suppository-15ml-OD; Tab DOLO-650mg-TID-oral; Tab RIVOTRIL-0.5MG-OD-oral. On the 2<sup>nd</sup> day there were complaints of dizziness and potassium levels were 3.0mEq/L, the CST(Contraction Stress Test) was positive, medicines advised was Tab VERTIN-8mg-TID-Oral; Syp POTKLOR-5ml-TID-oral; Tab SIBELIUM-5mg-OD-oral;Inj PAN-40mg-OD-iv. On the 3<sup>rd</sup> day, there were no other new chief complaints and CST was normal. On the 4<sup>th</sup> day, there were complaints of Akathisia and CST was positive and medications advised were Tab STUGERON-25mg-BD-oral(Stop Tab RIVOTRIL-0.5mg-OD-oral). On the 5<sup>th</sup> day there were no complaints and CST was positive, the medications given are Tab STUGERON-25mg-BD-oral. On the 6<sup>th</sup> day, the patient's condition was good and the potassium levels and CST was found to be normal. And finally on the 7<sup>th</sup> day the patient was doing well and was discharged with the following prescribed medications-

Tab DOLO-650mg-BD-Oral (SOS)

Tab VERTIN-8mg-TID-oral

Tab PAN-20mg-OD-oral

Tab SIBELLIUM-5mg-OD-oral

Tab STUGERON-25mg-OD-oral

Advised to review after 15days.

## **DISCUSSION:**

In this study, the frequency of vertigo and also the mean frequency, duration and intensity of migraine headaches per day were reduced significantly after 3 days of Cinnarizine [Tab STUGERON] therapy and the frequency of vertiginous episodes decreased with Flunarizine[Tab SIBELLIUM] treatment and severity of vertigo also improved.

## **CONCLUSION:**

The knowledge derived from these case report is, Cinnarizine[Tab STUGERON] and Flunarizine[Tab SIBELLIUM] plays a major role for the distinction of vestibular migraine from migraine with and without aura, as well as from basilar-type migraine treatment.

## **References**

1. Neuhauser HK, von Brevern M, Radtke A, Lezius F, Feldmann M, Ziese T, et al. Epidemiology of vestibular vertigo: a neurologic survey of the general population. *Neurology* (2005) 65(6):898–904. doi: 10.1212/01.wnl.0000175987.59991.3d

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

2. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population – a prevalence study. *J Clin Epidemiol* (1991) 44(11):1147–57. doi:10.1016/0895-4356(91)90147-2

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

3. Vukovic V, Plavec D, Galinovic I, Lovrencic-Huzjan A, Budisic M, Demarin V. Prevalence of vertigo, dizziness, and migrainous vertigo in patients with migraine. *Headache* (2007) 47(10):1427–35. doi:10.1111/j.1526-4610.2007.00939.x

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

4. Cha YH, Lee H, Santell LS, Baloh RW. Association of benign recurrent vertigo and migraine in 208 patients. *Cephalgia* (2009) 29(5):550–5. doi:10.1111/j.1468-2982.2008.01770.x

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

5. Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, et al. Vestibuläre Migräne: diagnostische Kriterien, Konsensusdokument der Bárány-Society und der International Headache Society. *Nervenarzt* (2013) 84(4):511–6. doi:10.1007/s00115-013-3768-x

[CrossRef Full Text](#) | [Google Scholar](#)

6. Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, et al. Vestibular migraine: diagnostic criteria. *J Vestib Res* (2012) 22(4):167–72. doi:10.3233/VES-2012-0453

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

7. International Headache Society. The international classification of headache disorders, 3rd edition (beta version). *Cephalalgia* (2013) 33(9):629–808. doi:10.1177/0333102413485658

[CrossRef Full Text](#) | [Google Scholar](#)

8. Stolte B, Holle D, Naegel S, Diener HC, Obermann M. Vestibular migraine. *Cephalalgia* (2014). doi:10.1177/0333102414535113

[CrossRef Full Text](#) | [Google Scholar](#)

9. Millen SJ, Schnurr CM, Schnurr BB. Vestibular migraine: perspectives of otology versus neurology. *Otol Neurotol* (2011) 32(2):330–7. doi:10.1097/MAO.0b013e3182040b21

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

10. Dieterich M, Brandt T. Episodic vertigo related to migraine (90 cases): vestibular migraine? *J Neurol* (1999) 246(10):883–92. doi:10.1007/s004150050478

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

11. Yoon MS, Katsarava Z, Obermann M, Fritzsche G, Oezyurt M, Kaesewinkel K, et al. Prevalence of primary headaches in Germany: results of the German Headache Consortium Study. *J Headache Pain* (2012) 13(3):215–23. doi:10.1007/s10194-012-0425-x

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

12. Neuhauser HK, Radtke A, von Brevern M, Feldmann M, Lezius F, Ziese T, et al. Migrainous vertigo: prevalence and impact on quality of life. *Neurology* (2006) 67(6):1028–33. doi:10.1212/01.wnl.0000237539.09942.06

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

13. Calhoun AH, Ford S, Pruitt AP, Fisher KG. The point prevalence of dizziness or vertigo in migraine – and factors that influence presentation. *Headache* (2011) 51(9):1388–92. doi:10.1111/j.1526-4610.2011.01970.x

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

14. Cutrer FM, Baloh RW. Migraine-associated dizziness. *Headache* (1992) 32(6):300–4. doi:10.1111/j.1526-4610.1992.hed3206300.x

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

15. Cass SP, Furman JM, Ankerstjerne K, Balaban C, Yetiser S, Aydogan B. Migraine-related vestibulopathy. *Ann Otol Rhinol Laryngol* (1997) 106(3):182–9. doi:10.1177/000348949710600302

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

16. Johnson GD. Medical management of migraine-related dizziness and vertigo. *Laryngoscope* (1998) 108(1 Pt 2):1–28. doi:10.1097/00005537-199801001-00001

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

17. Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T. The interrelations of migraine, vertigo, and migrainous vertigo. *Neurology* (2001) 56(4):436–41. doi:10.1212/WNL.56.4.436

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

18. Oh AK, Lee H, Jen JC, Corona S, Jacobson KM, Baloh RW. Familial benign recurrent vertigo. *Am J Med Genet* (2001) 100(4):287–91. doi:10.1002/ajmg.1294

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

19. Kayan A, Hood JD. Neuro-otological manifestations of migraine. *Brain* (1984) 107(Pt 4):1123–42. doi:10.1093/brain/107.4.1123

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

20. Kuritzky A, Toglia UJ, Thomas D. Vestibular function in migraine. *Headache* (1981) 21(3):110–2. doi:10.1111/j.1526-4610.1981.hed2103110.x

[CrossRef Full Text](#) | [Google Scholar](#)

21. Cha YH, Baloh RW. Migraine associated vertigo. *J Clin Neurol* (2007) 3(3):121–6. doi:10.3988/jcn.2007.3.3.121

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

22. Akdal G, Ozge A, Ergor G. The prevalence of vestibular symptoms in migraine or tension-type headache. *J Vestib Res* (2013) 23(2):101–6. doi:10.3233/VES-130477

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

23. Lempert T, Neuhauser H, Daroff RB. Vertigo as a symptom of migraine. *Ann N Y Acad Sci* (2009) 1164:242–51. doi:10.1111/j.1749-6632.2009.03852.x

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

24. Slater R. Benign recurrent vertigo. *J Neurol Neurosurg Psychiatry* (1979) 42(4):363–7. doi:10.1136/jnnp.42.4.363

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

25. Moretti G, Manzoni GC, Caffarra P, Parma M. “Benign recurrent vertigo” and its connection with migraine. *Headache* (1980) 20(6):344–6. doi:10.1111/j.1526-4610.1980.hed2006344.x

[CrossRef Full Text](#) | [Google Scholar](#)

26. Waterston J. Chronic migrainous vertigo. *J Clin Neurosci* (2004) 11(4):384–8. doi:10.1016/j.jocn.2003.08.008

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

27. Drummond PD. Triggers of motion sickness in migraine sufferers. *Headache* (2005) 45(6):653–6. doi:10.1111/j.1526-4610.2005.05132.x

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

28. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. *Cephalalgia* (2004) 24(Suppl 1):9–160. doi:10.1111/j.1468-2982.2003.00824.x

[CrossRef Full Text](#) | [Google Scholar](#)

29. Neuhauser H, Radtke A, von Brevern M, Lempert T. Zolmitriptan for treatment of migraineous vertigo: a pilot randomized placebo-controlled trial. *Neurology* (2003) 60(5):882–3. doi:10.1212/01.WNL.0000049476.40047.A3

[CrossRef Full Text](#) | [Google Scholar](#)

30. Furman JM, Marcus DA, Balaban CD. Rizatriptan reduces vestibular-induced motion sickness in migraineurs. *J Headache Pain* (2011) 12(1):81–8. doi:10.1007/s10194-010-0250-z

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

31. Baier B, Winkenwerder E, Dieterich M. “Vestibular migraine”: effects of prophylactic therapy with various drugs. A retrospective study. *J Neurol* (2009) 256(3):436–42. doi:10.1007/s00415-009-0111-3

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

32. Bikhazi P, Jackson C, Ruckenstein MJ. Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness. *Am J Otol* (1997) 18(3):350–4.

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [Google Scholar](#)

33. Maione A. Migraine-related vertigo: diagnostic criteria and prophylactic treatment. *Laryngoscope* (2006) 116(10):1782–6. doi:10.1097/01.mlg.0000231302.77922.c5

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

34. Gordon CR, Kuritzky A, Doweck I, Spitzer O, Shupak A, Hering R. Vestibulo-ocular reflex in migraine patients: the effect of sodium valproate. *Headache* (1993) 33(3):129–32. doi:10.1111/j.1526-4610.1993.hed3303129.x

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

35. Taghdiri F, Togha M, Razeghi Jahromi S, Refaeian F. Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. *SpringerPlus.* (2014) 3:231. doi:10.1186/2193-1801-3-231

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

36. de Bock GH, Eelhart J, van Marwijk HW, Tromp TP, Springer MP. A postmarketing study of flunarizine in migraine and vertigo. *Pharm World Sci* (1997) 19(6):269–74. doi:10.1023/A:1008617825269

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

37. Verspeelt J, De Locht P, Amery WK. Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. *Eur J Clin Pharmacol* (1996) 51(1):15–22. doi:10.1007/s002280050154

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

38. Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A. Flunarizine in the prophylaxis of migraineous vertigo: a randomized controlled trial. *Eur Arch Otorhinolaryngol* (2014) 271(11):2931–6. doi:10.1007/s00405-013-2786-4

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

39. Van Ombergen A, Van Rompaey V, Van de Heyning P, Wuyts F. Vestibular migraine in an otolaryngology clinic: prevalence, associated symptoms, and prophylactic medication effectiveness. *Otol Neurotol* (2014). doi:10.1097/MAO.0000000000000596

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

40. Lampl C, Katsarava Z, Diener H-C, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. *J Neurol Neurosurg Psychiatry* (2005) 76(12):1730–2. doi:10.1136/jnnp.2005.063750

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

41. Bisdorff AR. Treatment of migraine related vertigo with lamotrigine an observational study. *Bull Soc Sci Med Grand Duche Luxemb* (2004) (2):103–8.

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [Google Scholar](#)

42. Cologno D, d'Onofrio F, Castriota O, Petretta V, Casucci G, Russo A, et al. Basilar-type migraine patients responsive to lamotrigine: a 5-year follow-up. *Neurol Sci* (2013) 34(Suppl 1):S165–6. doi:10.1007/s10072-013-1384-y

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

43. Vitkovic J, Winoto A, Rance G, Dowell R, Paine M. Vestibular rehabilitation outcomes in patients with and without vestibular migraine. *J Neurol* (2013) 260(12):3039–48. doi:10.1007/s00415-013-7116-7

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

44. Mikulec AA, Faraji F, Kinsella LJ. Evaluation of the efficacy of caffeine cessation, nortriptyline, and topiramate therapy in vestibular migraine and complex dizziness of unknown etiology. *Am J Otolaryngol* (2012) 33(1):121–7. doi:10.1016/j.amjoto.2011.04.010

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)

45. Ferrari MD, Roon KL, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT<sub>1B/1D</sub> agonists) in acute migraine treatment: a meta-analysis of 53 trials. *Lancet* (2001) 358(9294):1668–75. doi:10.1016/S0140-6736(01)06711-3

[CrossRef Full Text](#) | [Google Scholar](#)

46. Silberstein SD, Dodick DW, Lindblad AS, Holroyd K, Harrington M, Mathew NT, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. *Neurology* (2012) 78(13):976–84. doi:10.1212/WNL.0b013e31824d5846

[Pubmed Abstract](#) | [Pubmed Full Text](#) | [CrossRef Full Text](#) | [Google Scholar](#)